+4.5% in five sessions: Virbac stock climbs 1.5% and approaches its 50-day moving average
The veterinary laboratory from Carros continues its recovery in mid-morning trading, in a Paris market oriented upward. The stock regains altitude after a very brief breakdown of support in early October, and returns to a technical zone it had abandoned.
A rebound that brings the stock into contact with its 50-day moving average
The Virbac stock gains 1.43% to €320.00, or nearly 4.4% over a week, while the SBF 120 advances 0.95%. The price is now in contact with the 50-day MA (€321.36), at just 0.4%, and 3.2% above the 20-day MA (€310.03). The stock had briefly broken through its support at €302 on October 1st before rebounding, which places this €302 zone at approximately 5.6% below the current price.
The 200-day MA (€344.09), 7% above, remains the most distant level. The RSI at 52 is neutral, following a movement that developed without excess.
A half-yearly publication that confirms objectives at the high end of the range
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Following the H1 2026 results published on September 17 after market close, Virbac reported organic growth of 7.4% and confirmed its annual objectives, now at the high end of its growth range. The stock had nevertheless declined 5.5% the following day, and remains down 0.9% over three months, with today's session being part of the recovery phase that followed. The group also published on October 6 a press release tracing the 30 years of its Thai subsidiary, whose revenue reached €13M in 2025.
A €1 billion share buyback program, announced on June 9, 2026, remains a context element for shareholders. For the stock, the level to watch is the 50-day MA at €321.36, which the price is almost touching.
SectorPharmacie et biotechnologies›Pharmacie, vaccins et santé animale
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 1 168 millions d'euros
Quarterly revenue: 1 168 millions d'euros
Guidance from the release
Notre solide performance à fin septembre 2026 nous permet de viser le haut de notre fourchette initiale de croissance du chiffre d'affaires
Risks mentioned
Effets de change défavorables impactant la croissance réelle (croissance réelle +5,9% vs +7,9% à taux constants)
Pression concurrentielle persistante sur les vaccins porcins en Asie de l'Est et pressions tarifaires au segment Animaux d'élevage
Exposition au Moyen-Orient et suivi des tendances inflationnistes (énergie) malgré anticipation d'impacts limités
Opportunities identified
Croissance soutenue des plateformes Supercharge (+11% environ) couvrant petfood, reproduction, dentaire, mobilité, otologie, endocrinologie et ruminants
Intégration fluide de Thyronorm dans la franchise d'endocrinologie avec contribution de +1 point de croissance et +0,5 point d'Ebit ajusté
Redémarrage réussi de la production du contrat majeur de façonnage en Amérique du Nord (juillet 2026) après contrainte réglementaire temporaire
Outlook / guidance
Expected revenue: 1 575 millions d'euros
Management commentary: « Bien que nos perspectives pour l'ensemble de l'année 2026 restent inchangées, notre solide performance à fin septembre (croissance de +7,9%) nous permet de viser la borne haute de notre fourchette de croissance du chiffre d'affaires de 5,5 % à 7,5 % à PCC »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
